PARSIPPANY, N.J., Jan. 11, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it will host an Investor Meeting on January 25, 2013 in New York. The meeting will begin at 8:00 a.m. EST and will be webcast simultaneously.
The meeting will be hosted by Watson's executive leadership team and will offer an in-depth look into the combined company following the acquisition of the Actavis Group.
Paul Bisaro, Watson's President and CEO, will provide a review of 2012 and the forecast for growth in 2013 and beyond. Todd Joyce, Watson's Chief Financial Officer, will provide a detailed review of financials, including an update on how the new company will report, expected synergies, the company's foreign exchange and tax positions and plan for deleveraging. Siggi Olafsson, President, Global Generics, will provide a detailed look at Watson's expanded global generics business that now spans more than 60 countries.
Fred Wilkinson, President, Global Brands, will offer insight into Watson's brands and biologics businesses — key growth drivers for the company's future — including an update on the brand pipeline, and Bob Stewart, President, Global Operations, will provide an update on Watson's expanded global supply chain.In-person attendance at the meeting is by invitation only. The webcast will be available live to investors and the media on Watson's Web site or at the following link: http://www.videonewswire.com/event.asp?id=91366. A replay of the webcast will be available approximately two hours following the completion of the event on the Company's Web site. About Watson Pharmaceuticals, Inc. Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. Watson is the world's third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Watson's global branded pharmaceutical business develops and markets products principally in Urology and Women's Health, and is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories. In addition, Watson is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business. Watson has announced that it will adopt a new global name – Actavis – effective in 2013. For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com. CONTACTS: Investors: Lisa DeFrancesco (862) 261-7152